tubocurarine
Trade name: curare
Approved
Feb 20, 1945
Tubocurarine, a naturally occurring alkaloid, is used to treat smoking withdrawl syndrom. Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH. Tubocurarine competes with acetylcholine for post-synaptic nicotinic NM receptors and blocks them. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 5 marketing orgs
Timeline
1940s
- Feb 20, 1945
Bristol-Myers — Earliest FDA Approval
- Feb 20, 1945
Bristol-Myers Squibb — NDA Secondary Org
- Feb 20, 1945
Bristol-Myers — NDA Organization
- Jan 30, 1947
Hospira — NDA Secondary Org
- Nov 28, 1947
Eli Lilly — Marketing Organization
- Nov 28, 1947
Eli Lilly — NDA Secondary Org
Indications
Approved for
Mechanism of action
Approval history
- approvedPriority reviewFeb 20, 1945
Chemistry & pharmacology
SMILES
COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]- Mol. weight
- 771.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3989821 ↗
- WikipediaTubocurarine chloride ↗
- NCATSW9YXS298BM ↗
- ChEMBLCHEMBL339427 ↗
- ChEMBLCHEMBL2063769 ↗
- ChEMBLCHEMBL1687 ↗
Also known as
- 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium
- 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium
- dextrotubocurarine chloride
- dtc
- dtc
- d-tubocurarine
- d-tubocurarine
- d-tubocurarine
- jexin
- jexin
- tubarine
- tubarine
- tubocurarin
- tubocurarin
- tubocurarine
- tubocurarine
- tubocurarine
- tubocurarine
- tubocurarine
- tubocurarine
- tubocurarine
- tubocurarine
- tubocurarine
- (+)-tubocurarine
- (+)-tubocurarine
- (+)-tubocurarine chloride
- tubocurarine chloride
- tubocurarine chloride
- tubocurarine chloride
- tubocurarine chloride
- (+)-tubocurarine dichloride
- tubocurarine hcl
- tubocurarine hydrochloride
Organizations
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Athenex, Inc. | For profit | MKTG | — |
| Bristol-Myers | For profit | NDA | Feb 20, 1945 |
| Bristol-Myers Squibb | For profit | NDA2 | Feb 20, 1945 |
| Eli Lilly | For profit | MKTG | Nov 28, 1947 |
| Eli Lilly | For profit | NDA2 | Nov 28, 1947 |
| Hospira | For profit | NDA2 | Jan 30, 1947 |